Helius Medical Technologies(US:HSDT)2026-03-31 01:53Financial Performance - Total revenue for the year ended December 31, 2025, was $6,017,000, a significant increase of $5,497,000 compared to $520,000 in 2024[369] - Staking revenue amounted to $5,469,000 for the year ended December 31, 2025, following the initiation of staking SOL holdings in September 2025[370] - Gross profit for 2025 was $5,517,000, a substantial improvement from a gross loss of $62,000 in 2024[369] - Selling, general and administrative expenses rose to $23,127,000 in 2025, an increase of $12,945,000 compared to $10,182,000 in 2024[373] - Total operating expenses surged to $249,357,000 in 2025, up from $13,841,000 in 2024, primarily due to unrealized losses on digital assets[369] - The net loss for 2025 was $40,890,000, compared to a net loss of $11,742,000 in 2024, reflecting a deterioration of $29,148,000[369] Cash Flow and Financing - Cash and cash equivalents increased to $7,282,000 as of December 31, 2025, compared to $1,088,000 in 2024[384] - Net cash used in operating activities was $16,514,000 in 2025, an increase of $5,473,000 from $11,041,000 in 2024[391] - The company generated $449,239,000 in net cash from financing activities in 2025, a significant increase from $6,954,000 in 2024[391] - The company issued shares under the 2025 ATM, generating net proceeds of $24,200,000 during the year ended December 31, 2025[386] Digital Asset Strategy - The company holds a total of 2,360,083 SOL tokens valued at $293.7 million based on a market price of $124.45 per token as of December 31, 2025[367] - The company has a strategic digital asset treasury strategy focused on acquiring SOL, which offers a ~7% native staking yield, and aims to leverage opportunities in DeFi and broader onchain activity[352] - The company has established a Master Loan Agreement to fund the acquisition of SOL and related treasury operations, with no outstanding loans as of December 31, 2025[355] Stock and Shareholder Actions - The company completed the issuance of 38,049,663 shares of Class A common stock at an offering price of $6.881, generating total gross proceeds of approximately $518.4 million before expenses[356][357] - The company has approved a stock repurchase program for up to $100 million of its outstanding Class A common stock, with 1,531,032 shares repurchased at a weighted-average price of $2.21 per share as of March 27, 2026[364] Market and Regulatory Environment - The price of SOL has experienced significant volatility, declining by 33% to $83.05 as of March 27, 2026, compared to $124.45 on December 31, 2025[367] - The company does not expect the One Big Beautiful Bill Act to have a material impact on its consolidated financial statements[350] Business Development - The company has entered into a Strategic Advisor Agreement with Pantera Capital and Summer for a term of two years to provide guidance on business operations and industry trends in the crypto technology sector[353] - The company began accepting prescriptions for its PoNS device in the U.S. in March 2022, with commercial sales commencing in April 2022[348] - The company has been actively seeking a business partner to commercialize and distribute the PoNS device in Australia, where it is authorized for sale as a Class IIa medical device[348] Accounting and Valuation - The company utilizes Monte Carlo and Black-Scholes option-pricing models to value derivative financial instrument liabilities[401] - The valuation model employs Level 3 inputs in the fair value hierarchy as per ASC 820 - Fair Value Measurement[401] - Information regarding recently issued accounting pronouncements is detailed in Note 2 of the consolidated financial statements[402] - There are no applicable quantitative and qualitative disclosures about market risk[403]